ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. It also develops remlifanserin, which is in phase 2 clinical trial for the treatment of alzheimer's disease psychosis and lewy body dementia psychosis; ACP-211, which is in phase 2 clinical trial to treat major depressive disorder; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; and ACP-271, a GPR88 agonist for the treatment of tardive dyskinesia and huntington's disease and is in phase I trial. In addition, the company develops ACP-2591, a cGP analogue which is in Phase 1 clinical trial to treat rett syndrome and fragile X syndrome; and STOKE Antisense Oligonucleotide Program, which is in discovery program for SYNGAP1 syndrome. It has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop, and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.…
ACADIA Pharmaceuticals Eyes Deals as DAYBUE Growth Fuels Revenue Surge
Acadia Pharmaceuticals (NASDAQ: ACAD) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 796 employees.
The shares were at 17.11 USD on 20 November 2026, down 24.1% over 52 weeks. Its 52-week range is 15.87 USD to 30.96 USD: the price is 44.7% below the high and 7.8% above the low.
At a market capitalisation of 2.96B USD, it trades at 8.1 times trailing earnings and 15.8 times forward earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.1, a discount of 76% for ACAD.
Acadia Pharmaceuticals reports return on equity of 31.9%, an operating margin of 10.2% and revenue up 22.8% year over year.
It holds more cash than debt, a net cash position of 904.59M USD. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 19 analysts cover the stock, with an average rating of Buy; their mean price target of 30.21 USD is 76.6% above the current price. The next earnings report is expected on 24 February 2027.